Kavish Patidar
@KavishPatidar11
Followers
368
Following
1K
Media
7
Statuses
280
transplant hepatologist; focus on hepatorenal syndrome & AKI in cirrhosis, critically ill patients with cirrhosis, and ETOH hepatitis. Thoughts are my own.
Houston, TX
Joined April 2022
Amazing multidisciplinary collaboration with rigorous adjudication at each site. Key points: *HRS is uncommon in the US (12.1%) *ATN is important and we need to start shifting our focus to this important etiology
Newly published @HrsHarmony study: Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US - Journal of Hepatology https://t.co/3a0IMxrsj9
5
13
50
Today is #HepatorenalAwarenessDay. We teamed up with @MNK_Pharma to bring you an Ask the Experts session for anyone wanting to better understand Hepatorenal Syndrome (HRS), especially HRS-AKI. Our expert panel breaks down what HRS is, why early detection is critical, and how
1
3
5
It’s a privilege (and very cool!) to be a colleague of a thought leader in MASH @NoureddinMD.
New in the @TheLancet :Arguably the highest fibrosis improvement in #MASH trials to date #livertwitter @ebtapper @schattenbergJ @AlkhouriNaim @akerotx @scottisaacsmd @NoureddinNabil @ArunJSanyalVCU Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic
1
0
6
Ready for some exciting discussions! @JoeCullaro @pummy92 @RegnerKR_Neph @KidneydrChirag Mitra Nadim @AASLDtweets
@nkf American Liver Foundation.
2
1
15
A much needed consensus. Led by @docsudhakodali1. @MethodistHosp
🔥Hot Topic in @LTxJournal! An international consensus conference was convened by the @_ILTS_ and the @ILCAnews to establish a more universal consensus regarding #livertransplantation for oncologic indications. 👀 Read the Consensus statement: https://t.co/kA6OLrplij
0
0
1
📣New data on cirrhosis recompensation in @JHepatology ✅Only 7% meets strict Baveno VII criteria ✅Expanded criteria capture ~38% with similar low mortality risk Recompensation: ⬇️systemic inflammation🔥 👍 improved hemodynamic ⬆️improved survival https://t.co/xPcE25dPcC
3
43
114
2
0
1
How common is ambulatory AKI (AKI occurring in an outpatient setting) in cirrhosis? ✅It’s common➡️1 in 8 ✅Underrecognized➡️42% ✅Key precipitants➡️hypovolemia 2/2 diuretics & GI losses, & nephrotoxin medication exposure ✅Deadly➡️1 in 8 ☠️at 90d 🔥🔥 https://t.co/imehINk3wv
cghjournal.org
Little is known about ambulatory acute kidney injury (A-AKI), which develops in an outpatient setting.
2
4
20
The jefe! My go to for anything related to methods and analysis plan. 🔥Liver risk score predicts liver related events with excellent performance in a diverse US veteran population.
0
2
9
💬 on a✈️ to 📝 with @AnandVKulkarni2 🔸So we all 🗣️AKI in CLD 🔸But ⁉️ESRD with ascites on consults (and they aren't uncommon) 🔸We dig deep -SAAG 🚫 -Causes: Mixed bag -Nephrogenic ascites 📈 ☠️ - 💊❓ Large gaps in 📝 @ebtapper @LiverFellow @AASLDtweets
https://t.co/H4wNWLM7Kb
journals.lww.com
d. However, patients with end-stage renal disease (ESRD) may also present with ascites even in the absence of cirrhosis. The literature on the management of patients with ESRD with ascites with or...
4
17
39
Original Article Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis Desplats et al. #LiverX
https://t.co/XYmg5dNepl
0
18
46
Artículo Original Corticosteroides en la hepatitis asociada a alcohol severa: No tan rápido: Una revisión sistemática de ensayos controlados aleatorizados. Shi, Pungwe et al. #LiverX
https://t.co/uVw97oSsZn
0
16
28
📣@ICA_Global_AKI published in @LancetGastroHep 🗺️3,821 patients with cirrhosis ✅38% had AKI ⚠️discrepancies in AKI management and outcomes ⚠️ AKI ➡️22.9% 28-day mortality 🎯Need for equitable & standardized care https://t.co/B24femgEfL
thelancet.com
This study found important regional differences in AKI severity, phenotype, management, and outcomes in patients with decompensated cirrhosis. Health-care coverage remains an important driver of...
5
33
84
What is the relationship btwn terlipressin & MAP From the genius of @JoeCullaro
https://t.co/wjtcnR9oWR 🔥post-hoc analysis, patient-level data from REVERSE and CONFIRM. 🔥In a time dependent model, 5 mmHg ⬆️ in MAP was associated with 1.17x the hazard of HRS-AKI reversal.
journals.lww.com
trials REVERSE and CONFIRM. Approach and Results: In this post hoc analysis we employed a linear mixed-effects model to assess terlipressin’s impact on MAP, exploring the relationship between MAP,...
2
5
18
Check out our latest article. Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: A randomized, single-blind clinical trial - JHEP Reports https://t.co/VizUMmEz2R
@JHEP_Reports @EASLnews @BavenoCoop @liverunitclinic
jhep-reports.eu
Continuous infusion of terlipressin may result in a more sustained reduction in portal pressure with fewer adverse effects than administered as a bolus. This study aimed to compare the hepatic and...
2
14
39
TCorticosteroids in severe alcohol-associated hepatitis? Not so fast! @avegailf @HEP_Journal @rabataller @KanwalFasiha @juanpabloarab @GCholankeril @KavishPatidar11 @KanwalFasiha @HowardTLeeMD @Dr_Vijay_Shah @magicbaby6 @AsraniSumeet
journals.lww.com
events. We aim to systematically review these variables and provide evidence-based recommendations for the inpatient and outpatient management of severe AH. Approach and Results: We performed a...
3
30
84
@KavishPatidar11 @md_myer @ebtapper @JoeCullaro ⏰ Early treatment of HRS-AKI is key, but how early is too early? Facts: 1️⃣volume responsive AKI is 3x more common than HRS-AKI 2️⃣HRS-AKI patients have effective hypovolemia by definition ➡️volume challenge is essential 3️⃣central volume overload? Terlipressin is not an option
0
3
15
Kickstarting the inaugural GLOBAL LIVER SAFETY EXPERTS @cancun with THE expert @nagachalasani
@avantsantemx @rajVuppaLanchi @orman_md @lilydaramd @craiglammertIU
0
0
12